Lexeo (NASDAQ: LXEO) awards COO 260,000 options and 65,000 RSUs

Rhea-AI Filing Summary

Lexeo Therapeutics granted its Chief Operating Officer, Jose Manuel Otero, new equity awards. On February 4, 2026, he received 65,000 shares of Common Stock in the form of restricted stock units at a price of $0 per share, bringing his beneficially owned Common Stock to 128,476 shares, including 112,733 RSUs.

He was also granted a stock option for 260,000 shares of Common Stock at an exercise price of $7.27 per share. For this option, 25% of the shares vest and become exercisable on February 4, 2027, with the remaining shares vesting in equal monthly installments over the following period, subject to his continued service. For the RSUs, 25% vest on February 15, 2027, with the rest vesting in equal quarterly installments on Lexeo’s standard quarterly vesting dates, also subject to continued service.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Otero Jose Manuel

Role Chief Operating Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	260,000	$0.00	--
Grant/Award	Common Stock	65,000	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 260,000 shares (Direct); Common Stock — 128,476 shares (Direct)

Footnotes (1)

1. The reported securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. Twenty-five percent (25%) of the RSUs shall vest on February 15, 2027, and 1/16th of the RSUs shall vest in quarterly installments thereafter on the Issuer's standard quarterly vesting dates, subject to the Reporting Person's continued service through each applicable vesting date. Includes 112,733 RSUs. 25% of the shares underlying the option vest and become exercisable on February 4, 2027, and 1/48th of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Otero Jose Manuel

(Last) (First) (Middle)

C/O LEXEO THERAPEUTICS, INC.

345 PARK AVENUE SOUTH, FLOOR 6

(Street)

NEW YORK NY 10010

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Lexeo Therapeutics, Inc. [ LXEO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/04/2026		A		65,000(1)	A	$0	128,476(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$7.27	02/04/2026		A		260,000		(3)	02/03/2036	Common Stock	260,000	$0	260,000	D

Explanation of Responses:

1. The reported securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. Twenty-five percent (25%) of the RSUs shall vest on February 15, 2027, and 1/16th of the RSUs shall vest in quarterly installments thereafter on the Issuer's standard quarterly vesting dates, subject to the Reporting Person's continued service through each applicable vesting date.

2. Includes 112,733 RSUs.

3. 25% of the shares underlying the option vest and become exercisable on February 4, 2027, and 1/48th of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service.

	/s/ Youjin Choi, Attorney-in-Fact	02/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What equity awards did Lexeo (LXEO) grant to its COO Jose Manuel Otero?

Lexeo granted its COO 65,000 restricted stock units and a stock option for 260,000 shares of Common Stock. The RSUs were granted at $0 per share, while the option carries an exercise price of $7.27 per share, subject to vesting conditions.

How do the 65,000 Lexeo (LXEO) RSUs granted to the COO vest?

The 65,000 RSUs vest over time. 25% vest on February 15, 2027, and the remaining 75% vest in 1/16th increments on the company’s standard quarterly vesting dates, conditioned on the COO’s continued service through each vesting date.

What are the terms of the 260,000 Lexeo (LXEO) stock options granted to the COO?

The COO received a stock option for 260,000 shares at an exercise price of $7.27 per share. 25% of the option vests on February 4, 2027, with the balance vesting in 1/48th monthly installments, contingent on continuous service.

How many Lexeo (LXEO) Common Stock shares does the COO beneficially own after this Form 4?

Following the reported grant, the COO beneficially owns 128,476 shares of Common Stock. This total includes 112,733 restricted stock units, each representing a contingent right to receive one share of Lexeo Common Stock, subject to vesting conditions.

Are the new Lexeo (LXEO) equity awards to the COO direct or indirect holdings?

Both the RSUs and the stock option reported are held as direct ownership by the COO. The Form 4 lists the ownership form for these securities as “D” for direct, with no indication of indirect entities such as trusts or partnerships.